Literature DB >> 5303905

Studies on vaccination against bacillary dysentery. 4. Oral immunization with live monotypic and combined vaccines.

D M Mel, B L Arsić, B D Nikolić, M L Radovanić.   

Abstract

Results of tests made in 1964 confirm the previous findings that live oral vaccine, prepared from streptomycin-dependent strains of shigellae, confers a strong, type-specific protection against acute bacillary dysentery. This vaccine did not reduce the carrier rate of shigellae. Observations on soldiers treated with a vaccine of Shigella flexneri serotypes 2a and 3 combined revealed no antagonizing effects from the type 3 component upon the protective effect of the 2a component contained in the same vaccine.

Entities:  

Mesh：

Substances：

Year:  1968        PMID： 5303905      PMCID： PMC2554416     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN： 0042-9686            Impact factor:   9.408


  2 in total

1.  Studies on vaccination against bacillary dysentery. 3. Effective oral immunization against Shigella flexneri 2a in a field trial.

Authors:  D M Mel; A L Terzin; L Vuksić
Journal:  Bull World Health Organ       Date:  1965       Impact factor: 9.408

2.  Studies on vaccination against bacillary dysentery. 2. Safety tests and reactogenicity studies on a live dysentery vaccine intended for use in field trials.

Authors:  D M Mel; R G Papo; A L Terzin; L Vuksić
Journal:  Bull World Health Organ       Date:  1965       Impact factor: 9.408
  2 in total
  31 in total

1.  Infectious disease.

Authors: 
Journal:  Br Med J       Date:  1973-01-13

Review 2.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

3.  Characterization of B-cell epitopes on IpaB, an invasion-associated antigen of Shigella flexneri: identification of an immunodominant domain recognized during natural infection.

Authors:  S Barzu; F Nato; S Rouyre; J C Mazie; P Sansonetti; A Phalipon
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

4.  Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines.

Authors:  A B Hartman; L L Van de Verg; H H Collins; D B Tang; N O Bendiuk; D N Taylor; C J Powell
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

5.  An environmental Escherichia albertii strain, DM104, induces protective immunity to Shigella dysenteriae in guinea pig eye model.

Authors:  Fatema Moni Chowdhury; Mohammed Ziaur Rahman; Sirajul Islam Khan; Chowdhury Rafiqul Ahsan; Nils-Kåre Birkeland
Journal:  Curr Microbiol       Date:  2014-01-23       Impact factor: 2.188

6.  Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen.

Authors:  K L Kotloff; D A Herrington; T L Hale; J W Newland; L Van De Verg; J P Cogan; P J Snoy; J C Sadoff; S B Formal; M M Levine
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

7.  Construction of a stable attenuated Shigella sonnei DeltavirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model.

Authors:  A B Hartman; M M Venkatesan
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

8.  Immunoproteome analysis of soluble and membrane proteins of Shigella flexneri 2457T.

Authors:  Amy V Jennison; Rubhana Raqib; Naresh K Verma
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

9.  Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains.

Authors:  D Mel; E J Gangarosa; M L Radovanovic; B L Arsic; S Litvinjenko
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

10.  Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains.

Authors:  A B Hartman; C J Powell; C L Schultz; E V Oaks; K H Eckels
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.